Change Condition: Overt HE
IBS-D
Male healthcare professional wearing a stethoscope against a bright green background.Male healthcare professional wearing a stethoscope against a bright green background.

Clinical resources
for managing
your adult patients
with overt
hepatic encephalopathy (HE)

Access experienced clinician perspectives, tools,
and educational material on diagnosing and
managing overt HE, including reducing the risk
of recurrence with XIFAXAN® (rifaximin)

Resource Topics to Explore

Male physician in white lab coat sitting at desk holding pen and writing on a clipboard while talking to a patient. Male physician in white lab coat sitting at desk holding pen and writing on a clipboard while talking to a patient.

Overt HE Symptoms and Diagnosis

What causes overt HE? Watch your peers discuss how they detect overt HE in patients with cirrhosis and download useful resources to help you assess.

Discover
Adult male in soft natural lighting with a dark green background. Adult male in soft natural lighting with a dark green background.

Managing Overt HE

How does overt HE impact patients? What is recommended for the management of patients at risk for overt HE recurrence? Watch patient case study videos and dive into clinical insights on best practices in managing patients with overt HE.

Learn
Female doctor reviewing medical information with a male patient during an office visit. Female doctor reviewing medical information with a male patient during an office visit.

XIFAXAN® (rifaximin) FOR OVERT HE

What does the clinical data say about XIFAXAN in patients with overt HE? How do I implement XIFAXAN in my practice? Access resources about XIFAXAN safety and efficacy, XIFAXAN dosing, and tools to help ensure your patients get access to treatment.

Access

GastroHub Spotlight

Grey play button with square border.Video

8 mins

Management Considerations After an Overt HE Episode

Featuring Rebecca McCollaum, NP

Follow along on the journey of Susan, who requires improved management after being hospitalized due to a recurrent overt HE episode.

DownloadDownload Case Overview

DON’T MISS NEW RESOURCES

Sign up to stay informed of updates to GastroHub

Sign Up Now

 
Question mark inside a white thought bubble on a green background. Question mark inside a white thought bubble on a green background.

Have questions about overt HE management with XIFAXAN? Request a rep.

A representative can schedule a time to visit your practice or assist you with ordering samples and accessing patient support materials.

Request a Rep
Calendar symbol inside of white thought bubble on green background. Calendar symbol inside of white thought bubble on green background.

Check for live and virtual conferences that may be relevant for your practice

Stay in the know and connect with your peers at upcoming live and virtual events.

See Events
See More

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • ​​XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
See Less

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • ​​XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
  • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
  • In clinical studies, the most common adverse reactions for XIFAXAN (alone or in combination with lactulose) were:
    –

    HE (≥10%): Peripheral edema (17%), constipation (16%), nausea (15%), fatigue (14%), insomnia (14%), ascites (13%), dizziness (13%), urinary tract infection (12%), anemia (10%), and pruritus (10%)

    –

    IBS-D (≥2%): Nausea (3%), ALT increased (2%)

  • ​​INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
  • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

XIF.0166.USA.24V3.0